Viking Therapeutics Stock: Analyst Bullish Despite Market Reaction

Viking Therapeutics Data Analysis

• 💡 Justin Zelin from BTIG believes the market's reaction to Viking Therapeutics' data is overdone.
• 🎯 Viking's data is considered comparable to, or even better than, that of Novo Nordisk and Eli Lilly.
• 🚀 The accelerated dose escalation schema in the trial led to tolerability issues, but the company plans to move to a less aggressive dosing schema.

Competitive Landscape and Market Share

• 📈 In the oral obesity class, Viking's data appears competitive and potentially class-leading.
• 🔑 A compelling aspect of the data was the maintenance dose at 90 mg, showing continued weight loss at 13 weeks after dose reduction.
• 💰 This maintenance dose presents a strong commercial argument and supports cost of goods scalability for manufacturing.

Tolerability and Trial Dropouts

• ⚠️ Tolerability issues were mostly front-ended, mild to moderate, and resolved by the third week for most patients.
• 📉 A 28% dropout rate in the first 3 months is attributed to higher grades of GI events, which is not unexpected for this drug class.
• ❓ The company has not yet selected its go-forward dose for Phase 3 trials, leaving flexibility for future decisions.

Analyst Outlook

• 🌟 Zelin maintains a buy rating on Viking Therapeutics with a $125 price target.
• 💬 He argues that investors are underappreciating the positive aspects of the presented data.